Eretofen has passed the preliminary examination of invention patents

Eriodictopine® (EretotopineTM) , a new type of animal “intestinal mucosal nutrition and repair additive” developed by Yanlin Houcheng Biotechnology (Beijing) Co., Ltd., has passed the patent preliminary examination and has entered the marketing stage. .

Eriodictopine® is a derivative of the natural flavonoid North American ergosin . According to experts from China Agricultural University and the Chinese Academy of Agricultural Sciences, Eriodictopine® has strong antioxidant activity, promotes intestinal epithelial cell proliferation, repairs damaged small intestine villus tissue, improves intestinal mucosal immune function, and relieves intestinal smooth muscle. Abnormal peristalsis, as well as a variety of biological activities that promote nutrient absorption.

The emergence of Eriodictopine® ( IretophenineTM) is expected to provide a new way of thinking and technical solutions to the problem of intestinal damage and piglet weaning stress in the current breeding industry. It is worthwhile for the farmers to continue to pay attention.